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OVERVIEW
Squamous cell carcinoma (SCC) represents the second most common histologic subtype of lung cancer (preceded only by adenocar-
cinoma). SSC of the lung is prevalently diagnosed in smokers and has been described as a preferentially centrally located tumor in which
the main airways are commonly involved. Clinically, it presents with predominant locoregional signs and symptoms, but in recent years
an increasing frequency of peripheral SCC of the lung has been reported. Pathologic diagnosis can be easily made through light
microscopy and immunohistochemistry. The treatment approach for early-stage disease does not differ from that of other histologic
subtypes of non–small cell lung cancer; in locally advanced unresectable or metastatic disease, doublet chemotherapy regimens
(including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine) remain the cornerstone
of front-line systemic treatment. Conversely, a single agent, mainly docetaxel, is the preferred treatment in second-line treatment. In
unselected patient populations, targeted therapies have been extensively tested in combination with cytotoxic chemotherapy with
disappointing results because of increased toxicity or lack of improvement in efficacy outcomes. Genomic alterations in SCC of the lung
have not been comprehensively characterized, and no molecularly targeted therapies have been specifically developed for the
treatment of this disease, but recently immune checkpoints have emerged as new therapeutic agent.
Lung cancer is the leading cause of cancer-related deathworldwide, with 1.4 million deaths estimated in 2010.1
Approximately 85% of the newly diagnosed lung cancers are
non–small cell lung cancer (NSCLC) and, among these, 20% to
30% are squamous cell carcinoma (SCC).2 SCC of the lung is
strongly associated with cigarette smoking and was, in the past,
the most common histologic subtype of lung cancer. Its inci-
dence has now been surpassed by adenocarcinoma, reflecting
trends in reduced tobacco exposure, with the introduction of
fıltered and low-tar cigarettes, as well as changes in cigarette
smoke inhalation patterns; nevertheless, SCC of the lung is still
responsible for 40,000 deaths annually in the United States.3
SCC is a preferentially centrally located tumor in which the
mainairways (trachea, carina, lobar, andsegmentalbronchi) are
commonly involved, which is responsible for symptoms and
signs such as cough, dyspnea, atelectasis, and obstructive pneu-
monia, as well as hemoptysis. In recent years, an increasing fre-
quencyof peripheral SCCof the lunghasbeen reported.Central
tumor necrosis with or without cavitation is a common radio-
logical fınding. SCC of the lung is the most common histotype
associated with Pancoast syndrome.
PATHOLOGY
SCC arises from dysplastic and metaplastic squamous epi-
thelium, and, in addition to the classic SCC, the World
Health Organization recognizes several additional histologic
patterns including papillary, clear cell, small cell, and ba-
saloid variants.4 In histologic specimens, SCC is defıned by
keratinization and/or intercellular bridges. In smears and
liquid-based preparations of well-differentiated SCC, intact
intercellular bridges and keratin pearls are uncommon,5
but they may be readily seen in cell block preparations.
Rather, squamous cells are characterized by dense dark blue
cytoplasm or orangeophilia onDiff-Quik and Papanicolaou-
stained slides, respectively. As SCC becomes less differenti-
ated, the aforementioned features become less prominent.
Poorly differentiated carcinomas form syncytial groups, es-
pecially in aspirates, and the cells have cyanophilic cyto-
plasm, higher nuclear/cytoplasmic ratios, and prominent
nucleoli.5
Most SCCs express highmolecular-weight cytokeratin, cy-
tokeratins 5/6 (CK5/6), and p63. Thyroid transcription
factor-1 (TTF-1) and cytokeratin 7 (CK7) are present in a
subset of cases, possibly as a result ofmixed adeno-squamous
phenotypes or non-specifıc staining. p63 has emerged as the
“front-runner” of the squamousmarkers.6 The perplexing is-
sue with p63 is its unexpected occasional presence in various
other tumor types, such as lung adenocarcinomas and lym-
phomas, as well as some sarcomas and various cancers (e.g.,
ovarian, endometrial, breast, and colorectal).
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p40 is a relatively unknown antibody that recognizes
Np63-a p63 isoform and was found to be highly specifıc for
squamous/basal cells. A large retrospective study compared
the standard p63 antibody (4A4) and p40 in a series of 470
tumors, which included lung SCCs (81 patients), adenocar-
cinomas (237 patients), and large cell lymphomas (152 pa-
tients). p63 was positive in 100% of SCCs, 31% of
adenocarcinomas, and 54% of large cell lymphomas (sensi-
tivity 100%, specifıcity 60%). In contrast, although p40 was
also positive in 100% of SCCs, only 3% of adenocarcinomas
and none of large cell lymphomas had p40 labeling (sensitiv-
ity 100%, specifıcity 98%). In summary, p40 is equivalent to
p63 in sensitivity for SCC, but it is markedly superior to p63
in specifıcity, which eliminates a potential pitfall of misinter-
preting a p63-positive adenocarcinoma or unsuspected lym-
phoma as a SCC.6
In the daily clinical practice, lung cancer immunohisto-
chemical characterizationmay be of additional value in those
20% to 30% of poorly differentiated NSCLC cases which do
not show a clear-cut differentiation at light microscope. A
panel of immunohistochemicalmarkers highlighting cell dif-
ferentiation lineages may be especially useful when the scant
diagnostic material does not allow a defınitive subtyping.
In a retrospective study, it has been shown that a four-
antibody panel approach, including CK7, CK5/6, TTF1,
and p63 (with the additional use of p40, napsin A, and
desmocollin-3 in discordant cases), contributed to refıne
lung cancer classifıcation in fıne needle aspiration cytology
cell blocks, remarkably reducing the NSCLC-not otherwise
specifıed diagnostic category.7
This cheap analysis can overlap the results obtained with
more expensive ($8 to $10 compared with hundreds of
U.S. dollars) and time-consuming (one day compared with
several days) molecular techniques, such as the investigation
of specifıc microRNAs, as proposed by Lebanony and
colleagues.8
CURRENT TREATMENT AND OUTCOME
Front-Line Management
The discovery of recurrent mutations in the epidermal
growth factor receptor (EGFR) kinase, as well as fusions in-
volving anaplastic lymphoma kinase (ALK), has led to a
marked change in the treatment of patients with lung adeno-
carcinoma. More recent data have suggested that targeting
mutations in BRAF, AKT1, ERBB2, and PIK3CA and fusions
that involve ROS1 and RET may also be successful.9 Unfor-
tunately, activating mutations in EGFR and ALK fusions are
typically absent in lung SCC,10 and targeted agents developed
for lung adenocarcinoma are largely ineffective against lung
SCC. The occasional detection of these mutations in samples
diagnosed as SCC is a result of challenges with the diagnosis
of adeno-squamous carcinoma and adenocarcinoma, which
can be largely resolved by comprehensive pathologic assess-
ment incorporating immunohistochemical markers.10
Historically, approaches to the treatment of NSCLC were
uniform, and histologic subtypes within NSCLC did not sig-
nifıcantly affect treatment decisions.11 Retrospective investi-
gation of some of the phase III studies investigating the role
of modern platinum-based doublets failed to detect a differ-
ential activity of one specifıc doublet according to histology,
and in one study squamous histology was associated with
better outcomes.12
For patients with locally advanced ormetastatic SCC of the
lung, two-drug chemotherapy regimens (including a plati-
num agent and a third-generation agent such as gemcitabine,
taxanes, or vinorelbine) currently remain the cornerstone of
treatment options.13 However, outcomes associated with
conventional therapies remain poor, underlining the clear
need for alternative approaches to treatment in this patient
population. Several studies14 have shown an inferior activity
of pemetrexed in combination with cisplatin in SCC of the
lung, and this agent is not currently licensed for the treatment
of this tumor type. These results may be related to a different
expression of thymidylate synthase (TS), one of the main en-
zymes of the folate pathway targeted by pemetrexed, in dif-
ferent histologic subtypes of NSCLC, leading to sensitivity to
pemetrexed which was lower in the SCC and higher in the
adenocarcinoma of the lung and prospective studies to vali-
date this hypothesis are currently underway.15
Recently, in a large phase III trial (1,052 patients), the effı-
cacy and safety of albumin-bound paclitaxel (nab-paclitaxel
[nab-PC]) plus carboplatin was compared with solvent-
based paclitaxel (sb-PC) plus carboplatin in advanced
NSCLC; objective response rate (ORR) was the primary out-
come. nab-PC demonstrated a signifıcantly higher ORR than
KEY POINTS
 Squamous cell carcinoma (SCC) of the lung is strongly
associated with cigarette smoking. Its incidence has now
been surpassed by adenocarcinoma, reflecting trends in
reduced tobacco exposure.
 On histologic sections, SCC is defined by keratinization
and/or intercellular bridges. By immunohistochemistry, it
express high molecular-weight cytokeratin, cytokeratins
5/6, p63, and p40. Thyroid transcription factor-1 and
cytokeratin 7 staining are present in a subset of cases.
 For patients with locally advanced or metastatic SCC of the
lung, two-drug chemotherapy regimens (including a
platinum agent and a third-generation agent such as
gemcitabine, taxanes, or vinorelbine) remain the
cornerstone of treatment options.
 To enhance chemotherapy response, the DNA damage
response may be targeted by reactivation of p53, by
inhibition of cell cycle checkpoints or by inhibition of DNA
repair processes, but none of these approaches have been
clinically validated at this time.
 In SCC there is no established role for targeted therapies
used either alone or in combination with chemotherapy.
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sb-PC (33% vs. 25%; p  0.005) and in patients with squa-
mous histology (41% vs. 24%; p 0.001). nab-PC was as ef-
fective as sb-PC in patients with nonsquamous histology
(26% vs. 25%; p 0.808). This improvement in ORR unfor-
tunately did not translate into any meaningful progression-
free and overall survival benefıt.16 This differential activity
might be partially attributable to aberrant caveolin-1 expres-
sion in SCC resulting in an higher intratumoral accumula-
tion.16 The expression of secreted protein acidic and rich in
cysteine (SPARC), which facilitates the accumulation of al-
bumin in the tumor and thus increases intracellular concen-
trations of the cytotoxic agent, has also been suggested.
SPARC expression has been linked to a higher response rate
in patients with head and neck cancers, which are predomi-
nantly of squamous histology.17
To enhance chemotherapy response, the DNA damage re-
sponse may be targeted by reactivation of p53, by inhibition
of cell cycle checkpoints, or by inhibition of DNA repair pro-
cesses.18 Platinum resistance, either intrinsic or acquired, is a
major clinical problem, as additional agents that can be
added to therapy in order to circumvent tumor resistance do
not currently exist. Platinum chemotherapy has been tested
with poly(ADP-ribose) polymerase (PARP) inhibition in
clinical trials. The rationale for the combination is based on
preclinical observations that PARP inhibitors preferentially
kill neoplastic cells and induce complete or partial regression
of a wide variety of human tumor xenografts in nude mice
treated with platinum chemotherapy.19 However, the full
function of PARP inDNA repair is not clear20 and, as a result,
the biologic mechanisms of chemosensitization of cancer
cells to platinum chemotherapy by PARP inhibition remain
to be resolved. Iniparib, initially developed as a PARP inhib-
itor, has a different mechanism of action from other PARP
inhibitors, because it forms a covalent bond. Additional pre-
clinical studies have shown that it induces g-H2AXmarker of
DNA damage, does not inhibit PARP1/2 at physiologic drug
concentrations, and potentiates cell cycle arrest induced by
DNA-damaging agents.21 This agent already entered phase
III clinical trials for breast cancer and NSCLC. The ECLIPSE
study, a phase III trial for patients with advanced squamous
cell lung cancer receiving a combination of carboplatin plus
gemcitabine either with or without iniparib, has recently
completed accrual, but data are not yet available. A previous
phase II study conducted in all NSCLC histologies failed to
show an improvement in response rate.21 Relatively little is
known about PARP1 protein levels and activity in normal
cells comparedwith tumor cells and how this contributes to a
therapeutic index when PARP inhibitors are used in con-
junction with DNA-damaging agents.
Histone deacetylases (HDACs) may also represent drug-
gable targets for the inhibition of DNA repair, as several class
I and class II HDACs (HDAC1–4) have been shown to pro-
mote DNA repair. A phase II study has been conducted in
NSCLC showing hints of activity.22 However, most current
inhibitors of epigenetic modifıers lack target specifıcity, and
genome-wide alterations may result in adverse effects on the
tumors or increase side effects when combined with chemo-
therapy. A better insight into themechanisms throughwhich
these compounds sensitize to chemotherapy may lead to the
identifıcation of relevant target genes and ultimately yield
more selective therapeutic strategies.18
Some studies have evaluated combinations of targeted
therapies plus standard-of-care chemotherapy. Increased
risk of bleeding has been reported in some, but not all, studies
evaluating vascular endothelial growth factor (VEGF) path-
way inhibitors as fırst-line therapy for advanced NSCLC in
patient populations that included squamous histology. In a
phase II study, four of 13 patientswith squamousNSCLCand
two patients with nonsquamous histology who received bev-
acizumab plus carboplatin and paclitaxel had severe life-
threatening hemorrhagic events,23 and this clinical toxicity
led to the exclusion of patientswith squamous histology from
the phase III studies investigating bevacizumab in NSCLC.
More recently, in a small phase II study performed in 31 pa-
tients with metastatic SCC of the lung, the rate of pulmonary
hemorrhage was low, but it was correctly concluded that
treatment of SCC of the lung with bevacizumab should be
considered experimental.24
Several multitargeted, antiangiogenic agents have been
studied in clinical trials for patients with advanced NSCLC.
Most of these agents inhibit the VEGF receptor (VEGFR),
and some also inhibit platelet-derived growth factor receptor
(PDGFR), BRAF, and EGFR. In a phase III study of carbo-
platin plus paclitaxel with and without sorafenib in fırst-line
advanced NSCLC, the primary endpoint of overall survival
(OS) was notmet and the studywas terminated early because
of the detrimental effect of sorafenib on patients with SCC
and lack of effect in the population with nonsquamous cell
carcinoma.25 Differently from what has been previously ob-
served with bevacizumab, in this study the life threatening
toxicities were multifactorial. Motesanib is a VEGFR-1, -2,
and -3, PDGFR, andKIT inhibitor that is currently in clinical
development in multiple tumor types, including NSCLC.
MONET-1 was another phase III trial investigating chemo-
therapy with or without motesanib (125 mg once daily); it
was temporarily suspended because of an increased risk of
hemoptysis in patients with squamous cell histology. These
patients discontinued the trial, the study subsequently re-
started, andmore than 1,000 patients with nonsquamous cell
histology were treated, but unfortunately the fınal effıcacy
analysis did not show any meaningful benefıt.26
A great deal of clinical interest was spurred by the early
results from a randomized phase II study of chemotherapy
with or without fıgitumumab, an antibody against insulin-
like growth factor type 1 receptor, which showed promising
activity in phase II studies, especially among patients with
squamous cell lung cancer,27 but unfortunately these data
are currently being reassessed because of an inaccurate data
analysis.
At present, only one study that enrolled patients with squa-
mous histology as part of a larger study in advanced NSCLC
(377 of 1,125 patients; 34%) demonstrated an OS benefıt.
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The FLEX study investigated the addition of cetuximab to
cisplatin plus vinorelbine and showed an improved OS of 1.2
months compared with chemotherapy alone in an open-
label, randomized phase III trial in patients with NSCLC.
When patients were stratifıed by EGFR expression according
to a semi-quantitative score, a higher percentage of SCCs of
the lung was seen in the high EGFR expression group. For
patients in the high EGFR expression group, OS was 2.4
month longer in the chemotherapy plus cetuximab arm (haz-
ard ratio, HR0.73, p0.011) while no corresponding ben-
efıt was seen in the low EGFR expression group. The
subgroup of patients with SCC and high EGFR score showed
the higher benefıt (HR0.62).28 Although some therapeutic
guidelines recommend the addition of cetuximab to chemo-
therapy for the management of metastatic NSCLC29 the
agent is not currently approved in Europe and in the United
States for this specifıc indication.
Immune checkpoints have emerged as new therapeutic tar-
gets. Blocking inhibitory pathways via monoclonal anti-
bodies, such as the anti-cytotoxic T-lymphocyte antigen-4
antibody, anti-programmed cell death-1 antibody, and anti-
programmed cell death-1 ligand antibody, has the ability to
break down the shield that tumors co-opt for their defense.
In a phase II study ipilumumab, an anti-cytotoxic T-cell
lymphocyte-4 monoclonal antibody, when administered
with carboplatin and paclitaxel according to a phased regi-
men (two doses of placebo plus carboplatin and paclitaxel
followed by 4 doses of ipilumumab plus carboplatin and pac-
litaxel then followed by a maintenance phase with ipilu-
mumab alone) showed a superior activity in SCC30. A phase
III study in SCC is currently ongoing.
SECOND-LINE THERAPY FOR ADVANCED NSCLC
The availability of tolerable and active therapeutic agents for
second- or third-line treatment also contributed to the im-
proved survival outcome noted with NSCLC in the last de-
cade. Randomized controlled trials have established the
effıcacy of pemetrexed, docetaxel, and erlotinib as salvage
treatment agents for patients with NSCLC whose disease
progressed after front-line therapy. Apart from the restric-
tion of pemetrexed to patients with tumors with a non-
squamous histology, the choice between these agents in
the salvage setting is driven primarily by drug toxicity pro-
fıle and patient choices. It is, however, conceivable that
the selection of EGFR kinase inhibitors will require the
demonstrable presence of activating EGFR mutations, simi-
lar to the practice standard in the front-line setting.31 Al-
though maintenance and second/third line phase III studies
with erlotinib32,33 showed survival improvement in the
overall treated population the benefıt was largely driven by
EGFR mutational status which is defınitively less frequently
detected in SCC.
However due to limited current treatment options an
ongoing phase III trial (LUX LUNG 8) compare the effı-
cacy of afatinib (BIBW 2992) versus erlotinib as second line
treatment in patients with SCC of the lung, as measured
by progression-free survival(ClinicalTrials.gov Identifıer:
NCT01523587).
A phase I trial of the anti-PD-1 antibody (BMS-936558)
administered once every 2 weeks included a large expansion
cohort of patients with NSCLC34. Patients with advanced
NSCLC who had been previously treated with a prior
platinum-containing regimen were eligible but could have
received no more than fıve prior treatment regimens for
their advanced disease. Besides being included in the dose-
escalation portion of the trial, patientswithNSCLCwere ran-
domly assigned to 1, 3, and 10 mg/kg to include equal
numbers of squamous and non-squamous cell histology at
each dose level. Of the 76 patients with NSCLC evaluable for
response, 14 patients had objective response (response rate,
18%). An unprecedented response rate of 33% was observed
among the 18 patients with SCC. Phase III studies are being
planned in the second-line treatment setting in advanced
NSCLC. Other anti PD-1 and antiPDL-1 antibodies are
currently being evaluated in phase I clinical trials.
CONCLUSION
SCC is a histologic subtype of lung cancer, easily diagnosed
through light microscopy or immunohistochemistry and
highly tobacco-related, which has a higher mutation rate
compared with lung adenocarcinoma. As opposed to adeno-
carcinoma, no established driver mutation has been defı-
nitely proven and no specifıc targeted therapy is currently
available.Doublet chemotherapy regimens (including cispla-
tin or carboplatin and a third-generation agent such as gem-
citabine, taxanes, or vinorelbine) remain the cornerstone of
the front-line systemic treatment, while a single agent,
mainly docetaxel, is the preferred treatment in the second-
line setting.
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